Main publications
Lodeserto P, Rossi M, Blasi P, Farruggia G, Orienti I. (2022). “Nanospermidine in Combination with Nanofenretinide Induces Cell Death in Neuroblastoma Cell Lines.” Pharmaceutics 14(6):1215. doi: 10.3390/pharmaceutics14061215. https://www.mdpi.com/1999-4923/14/6/1215
Orienti I, Farruggia G, Nguyen F, Guan P, Calonghi N, Kolla V, Chorny M, Brodeur GM. (2020) “Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor. “ Int J Nanomedicine 15:6873-6886. doi: 10.2147/IJN.S262032. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502401/
Orienti I, Nguyen F, Guan P, Kolla V, Calonghi N, Farruggia G, Chorny M, Brodeur GM. (2019) “A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model.” Drug Des Devel Ther. 13:4305-4319. doi: 10.2147/DDDT.S221909. https://pubmed.ncbi.nlm.nih.gov/31908416/
Orienti I, Salvati V, Sette G, Zucchetti M, Bongiorno-Borbone L, Peschiaroli A, Zolla L, Francescangeli F, Ferrari M, Matteo C, Bello E, Di Virgilio A, Falchi M, De Angelis ML, Baiocchi M, Melino G, De Maria R, Zeuner A, Eramo A. (2019) “A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells.” J Exp Clin Cancer Res. 38(1):373. doi: 10.1186/s13046-019-1383-9. https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1383-9
Orienti I, Francescangeli F, De Angelis ML, Fecchi K, Bongiorno-Borbone L, Signore M, Peschiaroli A, Boe A, Bruselles A, Costantino A, Eramo A, Salvati V, Sette G, Contavalli P, Zolla L, Oki T, Kitamura T, Spada M, Giuliani A, Baiocchi M, La Torre F, Melino G, Tartaglia M, De Maria R, Zeuner A. (2019) “A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. Cell Death Dis.” 10(7):529. doi: 10.1038/s41419-019-1775-y. https://www.nature.com/articles/s41419-019-1775-y